Molecular Partners AG (MLLCF)
USD 4.22
(0.24%)
USD 4.22
(0.24%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.65 Million CHF | -24.7% |
| 2022 | 4.85 Million CHF | -19.69% |
| 2021 | 6.03 Million CHF | -16.33% |
| 2020 | 7.21 Million CHF | 183.61% |
| 2019 | 2.54 Million CHF | 0.0% |
| 2018 | - CHF | 0.0% |
| 2017 | - CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.35 Million CHF | -8.24% |
| 2024 Q2 | 3.04 Million CHF | -9.01% |
| 2023 Q3 | 3.95 Million CHF | -7.06% |
| 2023 Q1 | 4.55 Million CHF | -6.16% |
| 2023 Q2 | 4.25 Million CHF | -6.57% |
| 2023 FY | 3.65 Million CHF | -24.7% |
| 2023 Q4 | 3.65 Million CHF | -7.59% |
| 2022 Q1 | 5.74 Million CHF | -4.92% |
| 2022 Q3 | 5.14 Million CHF | -5.45% |
| 2022 Q4 | 4.85 Million CHF | -5.79% |
| 2022 FY | 4.85 Million CHF | -19.69% |
| 2022 Q2 | 5.44 Million CHF | -5.17% |
| 2021 Q2 | 6.62 Million CHF | -4.26% |
| 2021 Q4 | 6.03 Million CHF | -4.66% |
| 2021 FY | 6.03 Million CHF | -16.33% |
| 2021 Q1 | 6.92 Million CHF | -4.07% |
| 2021 Q3 | 6.33 Million CHF | -4.45% |
| 2020 Q4 | 7.21 Million CHF | 0.0% |
| 2020 FY | 7.21 Million CHF | 183.61% |
| 2020 Q2 | 1.91 Million CHF | 0.0% |
| 2020 Q1 | - CHF | -100.0% |
| 2019 FY | 2.54 Million CHF | 0.0% |
| 2019 Q3 | 1.27 Million CHF | -59.53% |
| 2019 Q1 | 1.9 Million CHF | 0.0% |
| 2019 Q2 | 3.15 Million CHF | 65.95% |
| 2019 Q4 | 2.54 Million CHF | 99.14% |
| 2018 FY | - CHF | 0.0% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 0.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 FY | - CHF | 0.0% |
| 2017 Q1 | - CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1328.84% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -171.81% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -197.307% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 91.58% |
| GB Sciences, Inc. | 1.75 Million USD | -107.582% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | 20.871% |
| Zenith Capital Corp. | 10.22 Thousand USD | -35616.381% |
| Agentix Corp. | 50 Thousand USD | -7204.0% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 37.797% |
| Biomind Labs Inc. | 735.54 Thousand USD | -396.505% |
| ContraFect Corporation | 2.88 Million USD | -26.762% |
| CSL Limited | 12.18 Billion USD | 99.97% |
| CytoDyn Inc. | 30.07 Million USD | 87.857% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -915.262% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -479.612% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 91.984% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -285.122% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -382.938% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 87.731% |
| SQZ Biotechnologies Company | 27.47 Million USD | 86.706% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -311.232% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 91.137% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -57.011% |
| Mesoblast Limited | 118.7 Million USD | 96.923% |
| Marizyme, Inc. | 18.71 Million USD | 80.489% |
| Genus plc | 233.1 Million USD | 98.433% |
| Pharming Group N.V. | 171.54 Million USD | 97.871% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -386.933% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -152.503% |
| IMV Inc. | 28.88 Million USD | 87.356% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 35.458% |
| MultiCell Technologies, Inc. | 202.58 USD | -1802644.595% |
| ONE Bio Corp. | 19.71 Million USD | 81.476% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 93.647% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 88.967% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -20.68% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 71.901% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2480.59% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -14099.619% |
| Alpha Cognition Inc. | 1.22 Million USD | -199.253% |
| Enzolytics Inc. | 996.33 Thousand USD | -266.542% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 81.74% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 48.366% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.126% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 11.401% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -808.799% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -52.311% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1492.736% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2356.712% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -24.625% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2595.462% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -144.322% |
| Q BioMed Inc. | 4.1 Million USD | 11.143% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 82.035% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 94.601% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 22.486% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -61.709% |
| HST Global, Inc. | 98.31 Thousand USD | -3614.44% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1368.318% |
| Halberd Corporation | 150 Thousand USD | -2334.667% |
| Resverlogix Corp. | 6.49 Million USD | 43.737% |
| Cell Source, Inc. | 9.25 Million USD | 60.537% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -34.825% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1720.393% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -66.009% |
| Kadimastem Ltd | 891.22 Thousand USD | -309.773% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1631.011% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1359.737% |
| LadRx Corporation | 33.6 Thousand USD | -10767.107% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -382.938% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -1499.11% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 26.711% |
| Mobile Lads Corp. | 484.28 Thousand USD | -654.103% |
| International Stem Cell Corporation | 4.17 Million USD | 12.59% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | -89.714% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -937.951% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 53.299% |
| SYBLEU INC | 477.5 Thousand USD | -664.817% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2881.224% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1078.065% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 22.877% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -5751.345% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -67.454% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 56.085% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 57.461% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -134.783% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1262.687% |
| Neutra Corp. | 54.15 Thousand USD | -6643.482% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -99.563% |
| PureTech Health plc | 25.51 Million USD | 85.685% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -198.311% |
| IXICO plc | 472.02 Thousand USD | -673.691% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 76.44% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 94.135% |
| CSL Limited | 12.18 Billion USD | 99.97% |
| Cellectis S.A. | 92.77 Million USD | 96.064% |